DNA Damage/DNA Repair


The DNA in a human cell receives tens of thousands of damages per day due to both external (exogenous) and internal (endogenous) stress. The exogenous damages are caused by chemical contamination, UV light, ionizing radiation and alkylation/methylation etc, while the endogenous damages are coming from oxidation, alkylation and hydrolysis of bases etc. Since single strand and double strand breaks of DNA will occur after the damage, unrepaired DNA damage leads to cell senescent, apoptosis and malignancies etc. To overcome this threat, cell has developed DNA damage response, to detect DNA damage and mediate its repair.
DNA repair involves multiple mechanisms such as mismatch, base excision, and nucleotide excision repair etc. A group of proteins and pathways are participated in those processes. ATM/ATR kinases and DNA-PK are crucial for the detection of the DNA damage. Chromatin remodelers regulate chromatin accessibility for the DNA repair factors to function. RPA, Rad51 and the fanconi anemia proteins act directly on repairing the DNA damage. p53 network, the RAS GTPase superfamily, and the ubiquitin system also play important part in the DNA damage response. Aberrant DNA damage response is linked to aging, cancer and immune diseases.
-
BA3950 SF2523Summary: A potent and selective inhibitor. -
BA3951 ETP-45658Summary: ETP-45658 is an effective inhibitor. -
BA3952 YU238259Summary: YU238259 is a homology-dependent DNA repair inhibitor. -
BA3953 AMA-37Summary: AMA-37 is an analog of Arylmorpholine, a competitive inhibitor of ATP. -
BA3954 DNA-PK-IN-11Summary: DNA-PK-IN-11 is an inhibitor. -
BA3957 IMT1Summary: IMT1 is the first, specific and non-competitive inhibitor of human mitochondrial RNA polymerase. -
BA3962 IMP-1088Summary: IMP-1088 is a potent human N-myristoyltransferase and dual inhibitor. -
BA3964 PolQi2Summary: PolQi2 inhibits the deconjugating enzyme activity of Polθ. -
BA3966 NusinersenSummary: Nusinersen is an antisense oligonucleotide active molecule. -
BA3974 PTC299Summary: PTC299 is an orally active inhibitor of translation that selectively inhibits protein synthesis at the post-transcriptional level.

